Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidilizumab and Lenalidomide in Relapsed/Refractory Multiple Myeloma
NCT02077959Phase 1Terminated
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Mar 2014
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pidilizumab in multiple myeloma (MM), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate up to 30 days. Started Mar 2014; status: terminated.
02
Drugs
pidilizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02077959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077959.